A major drawback of therapeutic peptides is their rapid degradation and loss of function in the body. Lanthio Pharma B.V. has developed its bacteria-based peptide stabilization technology to provide libraries of peptides that are resistant to degradation, structured to improve efficacy and can be administered via oral or pulmonary delivery.

The basis of the company's technology is Lactococcus lactis, a bacterium that produces peptides containing lanthionine bridges. A lanthionine is composed of two alanine residues that are cross-linked by a thioether bond. Lanthionine bridges can span from two to 10 amino acids, and lock the resulting peptide into a specific conformation.